The partnership will allow Merck to use Iktos' generative design technology to develop a drug discovery program. Iktos' software creates virtual novel molecules for treating particular diseases. The company markets its AI technology as both services and software, it said; its AI software as a service (SaaS) software is called Makya and its AI SaaS platform, Spaya.

Merck invests $1B in Seagen
Merck has invested in oncology pharmaceutical developer Seagen in a deal worth $1 billion in equity investment.

New data from Merck, Kyorin shared to Pew's SPARK
Merck and Kyorin Pharmaceutical have shared antibiotic research data on the Pew Charitable Trusts' Shared Platform for Antibiotic Research and Knowledge...

Merck increases stake in Precigen
Merck is increasing its stake in Precigen from approximately 11.6% to 14.8% of outstanding shares through a convertible note with an outstanding principal...

Seattle Genetics, Merck partner on 2 oncology drug programs
Seattle Genetics and Merck will collaborate to develop and commercialize Seattle Genetics' ladiratuzumab vedotin, an antibody-drug conjugate. Separately,...